Search results
30 lis 2023 · In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
- Safety of Catheter Ablation Therapy for Atrial Fibrillation in Cardiac ...
In large observational studies or randomized trials, are the...
- Safety of Catheter Ablation Therapy for Atrial Fibrillation in Cardiac ...
Pulsed field ablation (PFA) is a safe and effective technology for catheter ablation of atrial fibrillation (AF). Multiple PFA-platforms for AF-ablation have been developed. ... 1 Department of Cardiology, Medical University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, ... AF=atrial fibrillation; ICD=implantable cardioverter ...
27 sie 2023 · Catheter ablation for patients with heart failure and atrial fibrillation has been shown to reduce arrhythmia burden, reverse left ventricular remodeling, and reduce mortality. 1–3,11–13 The...
13 sty 2022 · Highlights. •. We review current indications for catheter ablation in patients with atrial fibrillation (AF). •. Japanese guidelines recommend ablation for asymptomatic AF as a Class IIb level. •. Pulsed‐field ablation is a non‐thermal method with a superior safety compared to thermal methods. Summary.
30 paź 2024 · Abstract. Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common with a prevalence of 20-50% at one year after LVAD implantation.
14 lip 2023 · In large observational studies or randomized trials, are the safety and efficacy rates of catheter ablation for atrial fibrillation in patients with cardiac amyloidosis comparable to those observed in other cardiomyopathies?
30 lip 2023 · However, for VT in the setting of structural heart disease, catheter ablation is generally reserved for failure of drug-therapy or as adjunctive therapy in the setting of frequent implantable cardioverter-defibrillator (ICD) discharges
